Hatch-Waxman at 40: The Patent War Manual That Built a $445B Savings Machine, and a Drug Shortage Crisis
The Drug Price Competition and Patent Term Restoration Act of 1984 was not, in any conventional sense, a health policy […]
How to Identify Generic Drug Entrants Before FDA Approval: The Complete Pre-Approval Intelligence Playbook
Every year, the U.S. pharmaceutical market transfers hundreds of billions of dollars in revenue from branded monopolies to generic competitors.
The Influence of Emerging Markets on the Pharmaceutical Industry
Executive Summary: A Structural Recalibration of Global Power The global pharmaceutical sector is currently witnessing a definitive structural recalibration. The
The Influence of Emerging Markets on the Pharmaceutical Industry Read Post »
Dead Drugs Don’t Stay Dead: The Definitive IP, Regulatory, and Commercialization Playbook for Drug Repurposing
I. Executive Summary Drug repurposing — identifying new clinical indications for approved or investigational compounds — has moved from a
Drug Prices, Patent Cliffs, and Generic Competition: The Definitive US Pharma Strategy Guide
The US pharmaceutical market runs on a single, brutal equation: time equals money, and money equals survival. A company that
Valuation of Pharmaceutical Companies: A Comprehensive Analysis of Key Considerations
Welcome to the most volatile, high-stakes, and strategically critical discipline in modern business: the valuation of pharmaceutical and biotechnology companies.
Valuation of Pharmaceutical Companies: A Comprehensive Analysis of Key Considerations Read Post »
Generic Drug Opportunities: The Complete Framework for IP-Driven Market Entry, Regulatory Arbitrage, and Portfolio Construction
1. Executive Summary and Scope Finding a winning generic drug opportunity requires more than scanning the Orange Book for upcoming
Generic Drug Licensing and Repurposing: The Complete IP, Regulatory, and Commercial Playbook
Patent cliffs destroy revenue overnight. Generic competition can erase 80% of a blockbuster’s sales within twelve months of loss of
First Generic Launch has Significant First-Mover Advantage Over Later Generic Drug Entrants
Generic drugs perform better financially if they get to market first. The advantage is amplified if they get there more than one month ahead of competitors.
